ATE350043T1 - 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen - Google Patents

2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen

Info

Publication number
ATE350043T1
ATE350043T1 AT04777595T AT04777595T ATE350043T1 AT E350043 T1 ATE350043 T1 AT E350043T1 AT 04777595 T AT04777595 T AT 04777595T AT 04777595 T AT04777595 T AT 04777595T AT E350043 T1 ATE350043 T1 AT E350043T1
Authority
AT
Austria
Prior art keywords
hydroxycalciferol
1alpha
methylene
methyl
diseases
Prior art date
Application number
AT04777595T
Other languages
English (en)
Inventor
Hector F Deluca
Pawel K Grzywacz
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/657,533 external-priority patent/US6894037B2/en
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE350043T1 publication Critical patent/ATE350043T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04777595T 2003-07-03 2004-07-06 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen ATE350043T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61320103A 2003-07-03 2003-07-03
US10/657,533 US6894037B2 (en) 2003-07-03 2003-09-08 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses

Publications (1)

Publication Number Publication Date
ATE350043T1 true ATE350043T1 (de) 2007-01-15

Family

ID=34119196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04777595T ATE350043T1 (de) 2003-07-03 2004-07-06 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen

Country Status (10)

Country Link
EP (1) EP1641466B1 (de)
JP (1) JP4619360B2 (de)
AT (1) ATE350043T1 (de)
AU (1) AU2004260642B2 (de)
CA (1) CA2531294A1 (de)
DE (1) DE602004004134T2 (de)
DK (1) DK1641466T3 (de)
ES (1) ES2277293T3 (de)
MX (1) MXPA06000060A (de)
WO (1) WO2005011706A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646909A1 (en) * 2006-04-06 2008-03-27 Hector F. Deluca 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
ES2437921T3 (es) * 2009-10-21 2014-01-15 Wisconsin Alumni Research Foundation Método para prevenir la diabetes tipo 1
JP6035331B2 (ja) * 2011-06-14 2016-11-30 ウイスコンシン アラムニ リサーチ ファンデーション ３−デスオキシ−２−メチレン−１９−ノル−ビタミンｄ類似体およびそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6806262B2 (en) * 2000-05-31 2004-10-19 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds

Also Published As

Publication number Publication date
DE602004004134T2 (de) 2007-10-11
AU2004260642A1 (en) 2005-02-10
JP2007527399A (ja) 2007-09-27
ES2277293T3 (es) 2007-07-01
WO2005011706A1 (en) 2005-02-10
AU2004260642B2 (en) 2010-04-22
CA2531294A1 (en) 2005-02-10
JP4619360B2 (ja) 2011-01-26
DE602004004134D1 (de) 2007-02-15
MXPA06000060A (es) 2006-04-07
EP1641466A1 (de) 2006-04-05
EP1641466B1 (de) 2007-01-03
DK1641466T3 (da) 2007-05-14

Similar Documents

Publication Publication Date Title
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
BR9808010B1 (pt) Compostos de 2-alquil-19-nor-vitamina d e composição farmacêutica compreendendo os mesmos
GB0305929D0 (en) Organic compounds
ATE374178T1 (de) 2-alkylidene-19-nor-vitamin d verbindungen und ihre therapeutische verwendungen
CY1113654T1 (el) Αρυλ ουριες ως αναστολεις κινασων
NZ534445A (en) 1-apha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
ECSP055680A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
UY27834A1 (es) Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos.
CA2403232A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
DE60105035D1 (de) 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol und seine therapeutische verwendungen
DE60210805D1 (de) Substituierte indolizinähnliche verbindungen und ihre verwendung
MXPA03000405A (es) Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos.
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
ECSP055681A (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
ECSP045477A (es) COMPUESTOS DE AMIDAS DE ÁCIDO3-AMINO-TIENO[2,3-b]PIRIDINO-2-CARBOXÍLICO SUSTITUIDOY PROCEDIMIENTOS PARA PREPARARLOS Y SUS USOS.
ATE556999T1 (de) 2-propyliden-19-nor-vitamin d verbindungen
DE60229430D1 (de) (20s)-1 alpha-hydroxy-2-methylen-19-nor-bishomopregnacalciferol und ihre verwendungen
MX2007006262A (es) 2-metilen-19-nor-1a-hidroxi-17-en homopregnacalciferol y sus usos.
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
ATE534623T1 (de) 2-alkyliden-18,19-dinor-vitamin-d-verbindungen
DE602005022098D1 (de) 2-methylen-18,19-dinor-1alfa-hydroxy-homopregnacalciferol und dessen verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties